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Patient and Disease Characteristics Associate With Sensory
Testing Results in Chronic Pancreatitis
Louise Kuhlmann, MD,*†‡§ Søren S. Olesen, MD, PhD,*†§
Debbie Grønlund, MSc, PhD,†§ Anne E. Olesen, MSc, PhD,†§∥
Anna E. Phillips, MD,¶ Mahya Faghih, MD,#
and Asbjørn M. Drewes, MD, PhD, DMSc*†§
Background: Abdominal pain is the most common symptom in
chronic pancreatitis (CP) and has an extensive impact on
patients’ lives. Quantitative sensory testing (QST) provides
information on sensitivity to pain and mechanisms that can help
quantify pain and guide treatment. The aims of this study were
(1) to explore sensitivity to pain in patients with CP using QST
and (2) to associate patient and disease characteristics with QST
results.
Methods: Ninety-one patients with painful CP and 28 healthy
control participants completed a QST paradigm using static tests
(muscle pressure stimulation and electrical skin stimulations) to
unravel segmental and widespread hyperalgesia as a consequence of
visceral pain. A dynamic conditioned pain modulation (CPM)
paradigm was used as a proxy of pain modulation from the
brainstem to inhibit incoming nociceptive barrage, and ques-
tionnaires were used to gather information on pain experience and
quality of life.
Results: Patients had impaired CPM compared with controls
(18.0± 29.3% vs. 30.9± 29.3%, P= 0.04) and were hypersensitive to
pressure stimulation, specifically in the pancreatic (Th10) derma-
tome (P< 0.001). The capacity of CPM was associated with clinical
pain intensity (P= 0.01) and (in the univariate analysis only) the use
of opioids was associated with hyperalgesia to pressure stimulation
(P< 0.05).
Conclusions: Sensitivity to pain in CP patients can be characterized
by a simple bedside QST. Severe clinical pain in CP was associated
with reduced CPM function and should be targeted in management.
Key Words: chronic pancreatitis, pain, pain measurement,
hyperalgesia
(Clin J Pain 2019;35:786–793)
A bdominal pain is the most common symptom in chronicpancreatitis (CP) and is present during the clinical
course of the disease in up to 90% of patients.1,2 The pain is
often intense and long-lasting, and it is frequently associated
with malnutrition, opioid addiction, physical and emotional
disability, and major socioeconomic problems.3 Pain is a
symptom that has an extensive influence on patients’ well-
being and functional ability. Treatment of pancreatic pain
can, however, be difficult with unpredictable outcome.4
Studies on pancreatic pain are difficult to interpret, as vis-
ceral pain is a highly individual perception, which is difficult to
quantify.5 In the clinic, pain is affected by several confounders
such as comorbidities, anxiety, and side effects to medications,
which complicates the assessment of pain. To enable health care
providers to better characterize sensitivity to pain, experimental
models based on quantitative sensory testing (QST) can be used.
These techniques are based on the rationale that different neural
pathways and networks can be explored using standardized
stimulation with simultaneous recording of the evoked pain
response by psychophysical and/or objective methods.6–9
Because of convergence between visceral and somatic
afferent nerves at the spinal level, somatic QST can be used
indirectly to obtain information on pain sensitivity including
segmental (spinal) and central sensitization in the context of
visceral pain. In addition, QST may also provide knowledge on
the dynamic function of the pain system using, for example, the
CPM paradigm. This is an experimental paradigm designed to
activate endogenous pain inhibitory systems, whereby centers
in the brainstem gate incoming stimuli at the spinal cord. Both
static and dynamic QST paradigms have previously been used
in patients with CP and provided evidence for a malfunctioning
pain system with signs of central sensitization and deficient
inhibitory pain modulation.3,4,6,9 However, the association
between QST assessment parameters and patients’ and disease
characteristics remains unexplored.
In recent studies, QST has been used to characterize
pain sensitivity in different diseases including neuropathy,
chronic pelvic pain, irritable bowel syndrome, and func-
tional dyspepsia.10–13 In these studies, “transetiological”
patterns of sensory symptoms and deficits have been
observed, thus emphasizing that abnormal pain sensitivity is
universally observed across chronic pain conditions.14
Moreover, past studies have shown correlations between
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QST parameters and clinical pain characteristics,15 and QST
has been used in predictive contexts, wherein pretreatment
QST profiles were able to predict the outcome of surgery16
and treatment with analgesics.6,17
We hypothesized that somatic QST can be used to
characterize pain sensitivity in CP and that putative changes
would associate with clinical pain characteristics. The aims of
the study were as follows: (1) to show that a simple somatic
QST paradigm reveals significant and plausible differences in
pain sensitivity between patients with painful CP and controls
and (2) to investigate associations between clinical character-
istics of pain and pain sensitivity in CP patients.
MATERIALS AND METHODS
Study Oversight
This was a cross-sectional study including patients
with painful CP and healthy, pain-free volunteers as con-
trols. All participants provided written informed consent
before
the examinations, which were conducted at the Centre
for Pancreatic Diseases at Aalborg University Hospital,
Denmark, and the Department of Surgery at Radboud
University Nijmegen Medical Centre, Netherlands. The
protocol was approved by the local ethical committees and
medical agencies.
Patients
CP Patients
A total of 91 patients with CP from chronic
abdominal pain were included in the study. Inclusion
criteria included a minimum age of 18 years, CP diagnosis
based on the Lünenburg criteria with a score of ≥ 4,18,19
and chronic abdominal pain typical for CP (ie, dull
epigastric pain at least 3 days a week). Exclusion criteria
were generalized chronic painful conditions other than
CP and cognitive impairment hindering their ability
to follow instructions. Patients were instructed to con-
tinue their usual analgesic treatment on the day of the
examination.
A flowchart of the patient inclusion process is provided
in Figure 1.
Healthy Controls
Twenty-eight healthy, pain-free adults were included as
control group. Inclusion criteria included a minimum age of
18 years. Exclusion criteria included chronic or acutely
painful conditions, regular use of any kind of analgesics, and
pregnancy.
Procedures
Screening
Initially, all patients were screened according to the
inclusion and exclusion criteria; this included a detailed
patient history in the CP group to determine pain local-
ization and characterization, comorbidities, alcohol and
tobacco use, and medications. Opioid doses were converted
to morphine equivalents in milligrams.20 All patients com-
pleted a pain questionnaire (Brief Pain Inventory—short
form)21 and a quality of life questionnaire (EORTC QLQ-
C3022).
The patients were instructed to keep a pain diary record on
an 11-point Numeric Rating Scale every day for 1 week before
examination. The patients reported the highest pain score and
the average pain score experienced during the last 24 hours.
QST
QST was performed on all study participants using a
standardized test sequence. Three investigators were trained
in QST and performed the examinations.
Static QST Assessments. The static QST paradigm included
pressure stimulation and electrical stimulation. Pressure
stimulation thresholds were tested 1 time using an algometer
with a 1.0 cm2 probe (Somedic AB, Stockholm, Sweden).
The pressure thresholds were examined on the participant’s
right side at 5 different sites: below the midline of the
clavicula (C5 dermatome), pancreatic abdominal area,
above the umbilicus (abdominal Th10 dermatome), pancre-
atic site (just lateral of the spine in the dorsal Th10
dermatome), hip region on the anterior superior iliac spine
(L1 dermatome), and on the quadriceps muscle 5 cm
proximal to the patella (L4 dermatome). Two thresholds
were measured: pressure pain detection threshold and
pressure pain tolerance threshold (pPTT).6,7,23
Thresholds to electric constant current skin stimulation
(Digistim; Biometer A/S, Copenhagen, Denmark) with tet-
anic stimulation at 100 Hz were measured in the same der-
matomes, using 2 electrodes placed 3 cm apart.24 The
equivalents of the 2 thresholds were determined (electrical
pain detection threshold and electrical pain tolerance
threshold). These methods have previously been described in
detail.25
Dynamic QST Assessment. CPM is a clinically measurable
proxy of endogenous pain modulation. It can be exper-
imentally induced using a conditioning stimulus (eg, the cold
pressor test) and quantified by applying a test stimulation
before and after the conditioning stimulus.26 In this study,
the conditioning stimulus consisted of immersion of the
dominant hand in cold water (2.0 ± 0.3°C, continuously
stirred) for 2 minutes. If the pain became intolerable before
this point, the participants were allowed to remove their
hand from the water. The duration of cold pressor
stimulation was noted. The test stimulus was pressure
stimulation (pPTT) measured on the L4 dermatome on the
nondominant side, before the cold pressor test and
immediately after its completion. The CPM capacity was
quantified as the absolute and relative changes (%) in pPTT
before and after the conditioning stimulation.
Comprehensive QST batteries have previously been
recommended when examining pain sensitivity in chronic
pain patients.27 These batteries consisted of up to 13
examination modalities and were very time consuming. In
this study, we have focused on developing a QST paradigm
that was possible to perform at the bedside in a limited time,
Assessed for eligibility (n=149)
Excluded (n=58)
Declined to participate (n=35)
Not meeting inclusion criteria (n=4)
Other reasons (n=19)
Included and completed the study 
(n=91)
FIGURE 1. Flowchart of the inclusion process.
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consisting only of 4 elements designed to evaluate the most
important pain mechanisms. The need for specialized
equipment in this paradigm has also been kept at a
minimum.
Patient and Disease Characteristics
To examine whether clinical characteristics were asso-
ciated with QST results, the patient group was subdivided
according to pain intensity (mild to moderate: mean Visual
Analog Scale score ≤ 5/severe: > 5 in pain diary),28 presence
of diabetes mellitus,29 opioid consumption (yes/no),30 and
pain pattern (continuous/intermittent).31 Pain patterns were
based on the pain diaries; constant pain was defined as
persistent (daily) pain and intermittent pain as short periods
of pain separated by pain-free days.
Statistical Analysis
All data are presented as mean±SD or number (%)
unless otherwise indicated. Demographics, clinical data, and
CPM parameters of CP patients and controls were com-
pared by the Fisher exact test, Student t test, and 1-way
analysis of variance, as appropriate. The 1-way analysis of
variance tests were Bonferroni-corrected post hoc. Electrical
and pressure stimulation data were log transformed to
obtain a secondary normal distribution, and a mixed effects
model was used with CP/healthy participants as fixed effects
and stimulation site as a random effect, allowing us to
obtain an analysis of the overall difference on pressure/
electrical stimulation independent of the stimulation site. A
mixed effect model was also used for subanalysis of elec-
trical and pressure stimulation data, with clinical subgroups
as fixed effects and stimulation site as a random effect.
Univariate and multivariate regression analyses were per-
formed to investigate the association of clinical subgroups
with QST parameters. Correlations between electrical and
pressure stimulation data were analyzed using the Pearson
correlation coefficients.
A P-value ≤ 0.05 was considered statistically sig-
nificant. The software package STATA, version 15.1 (Sta-
taCorp LP, College Station, TX) was used for statistical
calculations.
RESULTS
A total of 91 CP patients and 28 controls completed the
study. Clinical and demographic characteristics of the 2
groups are presented in Table 1. The mean age of patients
was 52.6± 11.5 years compared with 44.1 ± 9.0 years in
controls (P< 0.001). The distribution of sex was propor-
tionate between patients and controls (male patients: 58%
vs. 50%; P= 0.44).
Sensitivity to Pain in Patients With CP and in
Healthy Controls
Pressure Stimulation
Overall, patients were hypersensitive to pressure stim-
ulation compared with healthy controls (P< 0.001). When
comparing the examined dermatomes separately, patients had
lower pressure pain threshold at all examined sites, albeit sig-
nificant differences were only seen for the dorsal pancreatic
dermatome (P=0.01), abdominal pancreatic dermatome
(P<0.001), and L4-control dermatome (P= 0.045) (Fig. 2).
Electrical Stimulation
There were no significant overall differences in elec-
trical pain thresholds between controls and patients
(P= 0.13), but an interaction between group and stimulation
site was seen (P= 0.002). Hence, differences in electrical
pain thresholds were confined to specific dermatomes, and,
when comparing the examined dermatomes separately,
patients had lower electrical pain threshold in the dorsal
pancreatic dermatome (P= 0.01) and L1-control dermatome
(P= 0.045) (Fig. 3).
TABLE 1. Clinical and Demographic Characteristics
CP Healthy
n 91 28
Male sex, n (%) 53 (58) 14 (50)
Age, mean ( ± SD) 52.6 ( ± 12) 44.1 ( ± 9)
BMI, mean ( ± SD) 22.8 ( ± 5) 24.4 ( ± 4)
Duration of CP, mean (± SD) (y) 14 ( ± 7)
Etiology (TIGAR-O), n (%)
Toxic-metabolic 43 (47)
Idiopathic 26 (29)
Genetic 12 (13)
Autoimmune 2 (2)
Recurrent and severe acute
pancreatitis
3 (3)
Obstructive 5 (6)
Alcohol consumption
Ongoing abuse,* n (%) 11 (12)
Amount, mean units per week ( ± SD) 6 ( ± 13)
Smoking
Current smoker, n (%) 65 (71)
Weekly amount, mean (± SD) 14 ( ± 12)
Analgetics
Patients treated with opioids, n (%) 69 (76)
Daily amount, mean (± SD) (mEq) 94 ( ± 124)
Range 0-750
Diabetes mellitus, n (%) 24 (26)
Patients treated with enzymes for
pancreatic exocrine insufficiency,
n (%)
48 (53)
*Alcohol-abusing patients were defined as female patients drinking > 7 U
of alcohol per week or male patients drinking > 14 U of alcohol per week.
BMI indicates body mass index; CP, chronic pancreatitis.
*
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*
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FIGURE 2. Pressure pain detection threshold in patients and
healthy control participants. *P<0.05.
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CPM
The mean duration of the cold pressor test was 56.4 sec-
onds (±41.6) for patients and 118.9 seconds (±5.7) for the
healthy controls (P<0.001). In controls, pPTT was
712±240kPa at baseline and 922±327 kPa after the con-
ditioning stimulation (P<0.001), and the absolute increase was
210±187kPa. In patients, pPTT was 693±276 kPa at baseline
and 794±307kPa after the conditioning stimulus (P<0.001),
and the absolute increase was 102±161 kPa. The relative
increase in pPTT (CPM capacity) was 30.9±29.3% in the con-
trol group compared with 18.0±29.3% in the patient group
(P=0.04). In the patients, there was no significant correlation
between the duration of the cold pressor test and the CPM
response (ρ=0.168, P=0.130).
To test whether age difference between patients and
controls influenced the results, a regression analysis was
performed and showed that neither the results of the pres-
sure test (P= 0.889), the electrical test (P= 0.411), or CPM
function (P= 0.602) were dependent on age.
Sensitivity to Pain in Patients With CP by Patient
and Disease Characteristics
The clinical and demographic characteristics of the
different subgroups are presented in Table 2.
Sensitivity to Pain by Pain Intensity
Patients with severe clinical pain had impaired mean
CPM capacity compared with patients with mild to mod-
erate pain and with controls (9.7 ± 23.2% vs. 22.7± 28.1%
vs. 30.9± 29.3%, P= 0.01) (Fig. 4). There was no difference
in the pain experienced during the cold pressor test in the
subgroups (P= 1.00). No other differences in QST param-
eters were observed between mild to moderate clinical pain
and severe clinical pain; pressure stimulation (P= 0.96) and
electrical stimulation (P= 0.97).
Sensitivity to Pain by Pain Pattern
There were no differences in QST parameters between
patients with constant and intermittent pain patterns with
regard to pressure stimulation (P= 0.67), electrical stimulation
(P=0.26), and CPM capacity (23.1±31.2% vs. 16.9±26.5%;
P=0.08).
Sensitivity to Pain by Opioid Treatment
Opioid-treated patients were hypersensitive to pressure
stimulation compared with their opioid-naive counterparts
(P<0.05). When comparing the examined dermatomes,
opioid-treated patients had lower pressure pain threshold at the
abdominal pancreatic dermatome (208±102 vs. 181±145;
P=0.01), while borderline significant differences were seen for
the dorsal pancreatic dermatome (432±225 vs. 354±207;
P=0.07) and L4-control dermatome (467±162 vs. 400±248;
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FIGURE 3. Electrical pain detection threshold in patients and
healthy control participants. *P<0.05.
TABLE 2. Demographic and Clinical Characteristics of the Patient Subgroups
N
Male
Sex,
n (%)
Age, Mean
(±SD)
BMI,
Mean
(±SD)
Duration of
CP, Mean
(±SD) (y)
Smoking,
n (%)
Exocrine
Insufficiency,
n (%)
CPM
Duration,
Mean
(±SD)
Daily Opioid
Amount,
Mean (SD)
Pain diary scores
Low VAS 47 31 (60) 54.4 ( ± 11) 22.2 ( ± 4) 13.1 ( ± 7) 42 (80) 24 (46) 52 ( ± 43) 83 ( ± 93)
High VAS 31 20 (60) 51.1 ( ± 10) 23.8 ( ± 6) 16.1 ( ± 7) 22 (67) 22 (66) 61.6 ( ± 49) 107 ( ± 140)
P 0.93 0.18 0.14 0.05 0.14 0.06 0.36 0.35
Pain pattern
Intermittent 10 7 (63) 51.7 ( ± 7) 24.3 ( ± 4) 11.6 ( ± 1) 11 (100) 6 (55) 61.1 ( ± 54) 68 ( ± 91)
Constant 66 41 (58) 52.8 ( ± 11) 22.7 ( ± 5) 14.8 ( ± 7) 50 (71) 38 (54) 55.9 ( ± 44) 95 ( ± 116)
P 0.71 0.76 0.30 0.17 0.04 0.92 0.74 0.46
Etiology
Alcohol 40 10 (23) 51.9 ( ± 9) 21.7 ( ± 4) 14.2 ( ± 5) 39 (91) 25 (58) 60.6 ( ± 48) 91 ( ± 95)
Other 44 18 (38) 53.3 ( ± 13) 23.8 ( ± 5) 13.8 ( ± 8) 30 (63) 23 (48) 52.7 ( ± 43) 95 ( ± 146)
P 0.001 0.57 0.03 0.81 0.002 0.33 0.43 0.87
Opioid treatment
Yes 63 45 (65) 53.2 ( ± 10) 22.5 ( ± 5) 14.9 ( ± 7) 53 (77) 40 (58) 53 ( ± 43) 0
No 21 8 (36) 51 ( ± 15) 23.9 ( ± 5) 6.2 ( ± 11) 16 (73) 8 (36) 66.9 ( ± 50) 124 ( ± 129)
P 0.02 0.44 0.21 0.04 0.70 0.02 0.23 .
Diabetes
Yes 22 14 (58) 52.4 ( ± 8) 24.9 ( ± 6) 15.8 ( ± 7) 17 (70.8) 18 (75) 59.6 ( ± 46) 97 ( ± 135)
No 62 39 (58) 52.7 ( ± 13) 22.1 ( ± 4) 13.3 ( ± 7) 52 (77.6) 30 (44.8) 55.3 ( ± 45) 84 ( ± 85)
P 0.99 0.89 0.01 0.14 0.51 0.04 0.70 0.64
BMI indicates Body Mass Index; CPM, Conditioned Pain Modulation; VAS, Visual Analog Scale.
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P=0.07) (Fig. 5). No other differences in QST parameters were
observed between opioid-treated and opioid-naive patients;
electrical stimulation (P=0.20) and CPM capacity (17.5±25.4
vs. 18.2±30.6; P=0.15).
Sensitivity to Pain by Diabetes
There were no differences in QST parameters between
diabetic and nondiabetic patients; pressure stimulation
(P= 0.97), electrical stimulation (P= 0.14), and CPM
(19.5 ± 25.1 vs. 18.2± 30.4; P= 0.15).
Multivariate Analysis
Table 3 summarizes the result of the multivariate
analysis for CPM. Clinical pain intensity (coefficient=
−3.7± 1.8%; P= 0.047) was independently associated with
less CPM capacity after adjusting for age, sex, diabetes, and
opioid consumption (Fig. 6). In contrast, the significant
difference in pressure stimulation thresholds when compar-
ing opioid-naive and opioid-treated patients, was lost in the
multivariate analysis (P= 0.30).
Correlations Between QST Parameters and
Questionnaires
Average pressure pain thresholds (mean of all stim-
ulation sites) were significantly correlated to the average
electrical pain thresholds (r= 0.38, P< 0.001) and the pain
interference score on the Brief Pain Inventory (r=−0.24,
P= 0.03). No other correlations were seen between the dif-
ferent QST parameters and questionnaire scores, as can be
seen in Table 4.
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TABLE 3. Multivariate Analysis of Conditioned Pain Modulation
Capacity (%) and Demographic and Clinical Variables
Variables
Coefficient
(95% Confidence Interval) P
Age* −1.8 (−7.9 to 4.4) 0.56
Male sex 1.93 (−11.2 to 15.0) 0.77
Pain diary score† −3.7 (−7.4 to −0.1) 0.047
Pain pattern (intermittent
vs. constant)
4.7 (−16.9 to 26.3) 0.67
Opioid treatment 2.6 (−18.2 to 13.0) 0.74
Diabetes −1.9 (−16.1 to 12.3) 0.79
*Coefficients are based on a change of 10 years of age.
†Coefficients are based on a change of 1 point on the Visual Analog Scale
for pain diary scores.
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FIGURE 6. Association between CPM capacity and pain diary
score from the data in the multivariate analysis. CPM indicates
Conditioned Pain Modulation; VAS, Visual Analog Scale.
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DISCUSSION
We investigated central sensitivity to pain in patients
with CP and in pain-free controls using a static and dynamic
QST paradigm and examined its association with patient and
disease characteristics. Patients were characterized by pressure
hyperalgesia, with the most pronounced changes observed for
the pancreatic dermatome and in patients on opioid-based
pain medication. Furthermore, a decreased CPM capacity
was seen in CP patients, which was independently associated
with clinical pain intensity. Sensitivity to pain was unrelated to
diabetes. These findings attest to the growing body of evidence
suggestive of abnormal sensitivity to pain in CP patients and
further support the use of somatic QST for pain character-
ization in this context.
Sensitivity to Pain in CP and Healthy Controls
We found that CPM capacity was impaired in the CP
group compared with controls. In addition, CP patients were
hypersensitive to pressure and electrical stimulations in the
examined locations. The reduced CPM capacity in CP
patients corresponds to results from previous studies.9,32,33
Systemic hyperalgesia in CP patients could indicate a change
in sensitivity to pain. It has previously been suggested that
patients with chronic pain have systemic sensitization secon-
dary to central reorganization and structural brain
changes.34–37 The patients in our study had been diagnosed
with CP at a mean of 14 years before testing. Their long
duration of disease may have resulted in a longer period of
remodeling, and it maybe that patients with shorter duration
of disease have shown lesser evidence of these changes.33
We have compared the results of this study with knowledge
gained in the clinic from assessing the results of more extensive
QST paradigms. We have found that these results are quite
similar to what has previously been shown in QST examinations;
however, no statistical validation has been performed.
Sensitivity to Pain and Clinical Parameters
Pain intensity was significantly associated with CPM
capacity in CP patients, as patients with severe pain had
more reduced CPM capacity compared with patients with
mild pain. Similar results have been seen in other diseases
such as irritable bowel syndrome, osteoarthritis, spinal cord
injury, and functional dyspepsia.13,15,38,39 Prolonged dura-
tion of the painful condition has resulted in lower CPM
capacity in both patients with CP and patients with
osteoarthritis.9,15 Taken together with our finding of asso-
ciation between CPM capacity and pain intensity, the data
indicate that impaired pain modulation is an important
mechanism in chronic pancreatic pain. However, the ques-
tion of whether reduced CPM capacity is caused by
persistent severe pain, or is actually the cause for developing
severe pain, remains unsolved. The predictive value of CPM
function in the context of treatment has previously been
studied. Bouwense et al40 found that CPM function pre-
dicted the efficacy of treatment with pregabalin in CP.
Diabetes can cause hyposensitivity due to neuropathy,41,42
but we found no association between the presence of diabetes
and pressure stimulation, electrical stimulation, or CPM
capacity, and all patients with symptoms of other painful
conditions were excluded. These data suggest that, if any of the
patients had an undiagnosed neuropathy, it did not seem to
have an effect on the results, as the QST results of the diabetic
group and the nondiabetic group were quite similar.
Of note, patients on opioid pain management regimens
were found to be hypersensitive to pressure stimulation in
univariate analysis compared with their opioid-naive counter-
parts. One explanation for this could be that these patients
experience more severe pain (the reason for the opioid therapy)
or, in some cases, opioid-induced hyperalgesia. In our study,
the association was lost in the multivariate analysis, potentially
due to type II error in the setting of a small sample size.
When looking at pain patterns over time, a previous
study has found that patients with intermittent pain were
more likely to respond to treatment than those with a more
stable pain profile.43 It has been suggested that patients with
continuous pain have a more stabilized and irreversible central
sensitization, which is a sign of end-stage pain chronification
with severe central neuroplastic changes that are less prone to
respond to treatment.44 These findings were not reproducible
in this study, as pain pattern was not significantly associated
with QST parameters. This could be explained by the rela-
tively short baseline pain registration, which might not be
sufficient to illustrate the pain pattern thoroughly.
In the current study, there was no screening for
comorbidities such as anxiety and depression, which may
influence the results. However, the lack of correlation
between life quality and QST results suggest that such
symptoms are likely not of major importance in this study.
Pain sensitivity has been quantified using somatic QST,
although the pain in CP is visceral. This could, in theory, be a
source of error, as it is an indirect measurement. However,
variations with QST similar to those found in the clinical
subgroups of the CP patients have previously been seen in
various somatic pain conditions, implying that this variation is
not caused by the indirect measurements relating to the pan-
creas, but rather to central changes in the pain system.10,15,45,46
Strengths and Limitations
QST has been widely used in pain research over the
past 40 years, and, especially, the static tests have shown a
TABLE 4. Intercorrelations Between QST Parameters and Correlations With BPI and QOL Scores
CPM ePDT pPDT
Correlation Coefficient P Correlation Coefficient P Correlation Coefficient P
BPI pain severity score −0.03 0.78 0.04 0.69 0.11 0.32
BPI pain interference score 0.08 0.45 −0.09 0.40 −0.24 0.03
EORTC QLQ score 0.03 0.77 −0.05 0.65 −0.05 0.65
pPDT 0.07 0.46 0.38 < 0.001
ePDT −0.01 0.93
Bold values indicates significant values.
BPI indicates Brief Pain Inventory; CPM, Conditioned Pain Modulation; EORTC QLQ, the European Organization for Research and Treatment Quality of
Life Questionnaire; ePDT, electrical pain detection threshold; pPDT, pressure pain detection threshold; QOL, quality of life; QST, Quantitative Sensory Testing.
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high degree of standardization and reproducibility.7
Dynamic QST tests in chronic pain patients have suffered
from large variability between patients and poor day-to-day
reproducibility in patients with CP. Although dynamic tests
such as CPM are encumbered by this variability, an argu-
ment to be made is that substantial variability over time in
the CPM paradigm must be expected, given the necessarily
reactive and dynamic nature of the modulation of noci-
ceptive inputs.7,47 The fluctuating nature of chronic pan-
creatic pain may also contribute to the variability. We have
considered this in our analysis of dynamic QST results and
performed our testing in a standardized manner to limit
unnecessary variability.
In addition, an age difference was seen between patients
and controls, with the patients being of more advanced age.
Previous studies have shown that advancing age can affect the
QST results,48,49 but when examining whether the age differ-
ences influenced the results of the tests, no connection was
found. We, therefore, conclude that the age difference did not
affect the results of this study.
There was also a difference in the duration of the cold
pressor test between patients and controls. However, no corre-
lation between the duration of the cold pressor test and the
magnitude of CPM response in patients was found, and this
could suggest that the patients’ CPM response is already chron-
ically activated to its maximum, thereby not allowing for further
increase, and this could even result in facilitation of the pain.
As a comparator, one could reflect on whether it is
optimal to use healthy volunteers or whether a control
group consisting of patients with similar comorbidities and
other characteristics (ie, alcohol consumption, smoking
habits, etc.), for example, a group consisting of patients with
pain-free CP, would be better suited. We will focus on elu-
cidating this aspect in future studies.
The data concerning the patients compared with healthy
volunteers are, however, not the main finding of this study. It
is a result in line with previous studies in CP and QST and is,
therefore, mainly interesting in the fact that it confirms that
the results of this study probably can be transferred to the
general population of patients with painful CP.
In this study, we compared CP patients on opioid
management regimes with their opioid-naive counterparts,
but we did not include a control group on opioid manage-
ment regimens due to nonabdominal pain. It is, therefore,
difficult to elucidate the full effects of opioids on QST
results, and we plan to include this in future studies.
In this study, we did not examine psychiatric comor-
bidities such as anxiety and depression, although this could
influence the patient pain report, as psychiatric comorbid-
ities can change the patients’ experience of pain. All results
should, therefore, be evaluated with this in mind. As a
consequence, we have included a screening of psychiatric
comorbidities in the examination at our clinic to ensure that
the examination is thorough and exhaustive.4,50
Clinical Perspective: Mechanism-based
Treatment
The choice of analgesic used to treat pancreatic pain, is
typically based on local traditions and the treating physician’s
personal experience and preferences, and, in severe pain,
opioids are often needed. For some practitioners and patients,
opioids play an integral part in the treatment of persistent
severe pain. Although opioids can provide effective analgesia,
they are also associated with considerable side effects, and a
high risk of addiction.51 Several studies point to the fact that
patients can benefit from a more individualized treatment
approach with a focus on pain mechanisms.4,25,52 QST can be
used to characterize the patient’s sensitivity to pain and
thereby improve the possibility of individualizing treatment
according to affected pain mechanisms.53,54 For example, it
has been shown that pregabalin has moderate inhibitory
effects on central sensitization, and this effect can be predicted
by static QST.6 Likewise, a reduced CPM capacity can be
potentiated with either tapentadol or duloxetine, and the
clinical effect of such treatment is predictable by dynamic
QST.17,55 CPM function has also shown to be predictive of
pregabalin’s treatment effect in patients with CP.40
Our study provides a simple QST protocol that can be
applied in the clinic, with results that are comparable to
prior literature comparing CP patients with controls.9,33 Its
simplicity makes it amenable to bedside examination in the
clinical setting. Incorporating this protocol into clinical
evaluation of pancreatic pain represents a feasible and
important improvement in the evaluation of pancreatic
pain, as recommended in international treatment guidelines
(Drewes and colleagues). This study does not provide suf-
ficient control material to estimate reliable QST-based cut-
off values, but this will be the next step in developing a
validated QST-based treatment guideline.50
CONCLUSIONS
The clinical characteristics of CP patients associate with
objective quantitative testing of the pain system. The main
finding was that severe clinical pain was associated with
decreased CPM capacity. This discovery, via the use of
quantitative sensory testing, may represent a paradigm shift in
clinical evaluation and treatment of CP. These findings further
emphasize that changes in sensitivity to pain are important.
Future studies should address how quantitative sensory testing
can be used to predict disease course and treatment response.
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